RNXT vs. FLGC, BIVI, HUGE, GLTO, VINC, LUMO, YMTX, ONTX, SYBX, and NERV
Should you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include Flora Growth (FLGC), BioVie (BIVI), FSD Pharma (HUGE), Galecto (GLTO), Vincerx Pharma (VINC), Lumos Pharma (LUMO), Yumanity Therapeutics (YMTX), Onconova Therapeutics (ONTX), Synlogic (SYBX), and Minerva Neurosciences (NERV). These companies are all part of the "pharmaceutical preparations" industry.
RenovoRx (NASDAQ:RNXT) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, community ranking, valuation and earnings.
Flora Growth received 7 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 59.09% of users gave Flora Growth an outperform vote while only 37.50% of users gave RenovoRx an outperform vote.
RenovoRx has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Flora Growth has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500.
In the previous week, RenovoRx had 2 more articles in the media than Flora Growth. MarketBeat recorded 4 mentions for RenovoRx and 2 mentions for Flora Growth. Flora Growth's average media sentiment score of 0.72 beat RenovoRx's score of 0.00 indicating that Flora Growth is being referred to more favorably in the news media.
RenovoRx presently has a consensus target price of $8.50, indicating a potential upside of 614.29%. Flora Growth has a consensus target price of $7.00, indicating a potential upside of 323.99%. Given RenovoRx's higher possible upside, research analysts clearly believe RenovoRx is more favorable than Flora Growth.
RenovoRx has a net margin of 0.00% compared to Flora Growth's net margin of -75.33%. Flora Growth's return on equity of -60.26% beat RenovoRx's return on equity.
3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 9.0% of RenovoRx shares are owned by insiders. Comparatively, 17.6% of Flora Growth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
RenovoRx has higher earnings, but lower revenue than Flora Growth. RenovoRx is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.
Summary
Flora Growth beats RenovoRx on 11 of the 17 factors compared between the two stocks.
Get RenovoRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RenovoRx Competitors List
Related Companies and Tools
